Mease, P. J., S. Chohan, F. J. Garcia Fructuoso, A. B. Gottlieb, R. C. Chou, A. M. Mendelsohn, and M. E. Luggen. “Randomized, Double-Blind, Placebo-Controlled, Multiple-Dose, Phase 2b Study to Demonstrate the Safety and Efficacy of Tildrakizumab, a High-Affinity Anti–Interleukin-23P19 Monoclonal Antibody, in Patients With Active Psoriatic Arthritis”. SKIN The Journal of Cutaneous Medicine, vol. 4, no. 5, Sept. 2020, p. s43, doi:10.25251/skin.4.supp.43.